BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 33201837)

  • 41. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
    Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
    PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive Analysis of N6-Methylandenosine-Related lncRNAs in Clear Cell Renal Cell Carcinoma: A Correlation With Prognosis, Tumor Progression, and Therapeutic Response.
    Meng C; Li J; Wang X; Ying Y; Li Z; Wang A; Li X
    Cancer Invest; 2024 Apr; 42(4):278-296. PubMed ID: 38644691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
    Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
    Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma.
    Xiao W; Wang T; Ye Y; Wang X; Chen B; Xing J; Yang H; Zhang X
    Aging (Albany NY); 2021 Jan; 13(3):3536-3553. PubMed ID: 33495417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Golgi Alpha-Mannosidase II as a Novel Biomarker Predicts Prognosis in Clear Cell Renal Cell Carcinoma.
    Li C; Guo L; Chen F; Yu W; Rao T; Ruan Y
    Oncol Res Treat; 2020; 43(6):264-275. PubMed ID: 32403105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
    Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
    Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. STAT3 regulates miR93-mediated apoptosis through inhibiting DAPK1 in renal cell carcinoma.
    Du Y; Kong C
    Cancer Gene Ther; 2021 May; 28(5):502-513. PubMed ID: 33230258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
    Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
    Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
    Ruan H; Li S; Bao L; Zhang X
    Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
    Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
    Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma.
    Yao D; Xia S; Jin C; Zhao W; Lan W; Liu Z; Xiu Y
    Cell Cycle; 2020 Sep; 19(17):2195-2206. PubMed ID: 32783497
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 55. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.
    Zheng J; Wang L; Peng Z; Yang Y; Feng D; He J
    EBioMedicine; 2017 Feb; 15():62-72. PubMed ID: 27993630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.
    Mitsui Y; Chang I; Fukuhara S; Hiraki M; Arichi N; Yasumoto H; Hirata H; Yamamura S; Shahryari V; Deng G; Wong DK; Majid S; Shiina H; Dahiya R; Tanaka Y
    BMC Cancer; 2015 Dec; 15():942. PubMed ID: 26626260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma.
    Ma X; Gu L; Li H; Gao Y; Li X; Shen D; Gong H; Li S; Niu S; Zhang Y; Fan Y; Huang Q; Lyu X; Zhang X
    J Transl Med; 2015 Feb; 13():56. PubMed ID: 25740019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.